Evaluating safety of preservative-free treprostinil in children with pulmonary arterial hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and tolerability of preservative-free parenteral treprostinil in pediatric patients diagnosed with pulmonary arterial hypertension (PAH). Participants, aged from birth to under 18 years, will receive either subcutaneous or intravenous treprostinil and will be monitored for a duration of 20 weeks. The study focuses on both treatment-naïve patients and those previously treated with other formulations of treprostinil. The goal is to determine if the preservative-free formulation is safe for use in this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed informed consent by the parents or the legal representatives and written assent from appropriately aged participants
2. Males or females from birth to under 18 years of age at the time informed consent was signed
3. Confirmed diagnosis of severe PAH classified as PH Group 1 requiring a treatment with prostacyclin infusion
4. Current diagnosis of PAH confirmed by right heart catheterisation (RHC) at screening or by historical RHC prior to screening with following haemodynamic findings:

   * Mean pulmonary arterial pressure (mPAP) \>20 mmHg
   * Pulmonary vascular resistance Index (PVRI) \>3 Wood Units (WU) m² If RHC is not possible due to medical reasons (e.g. neonates and infants), the confirmation by ECHO at the screening is sufficient.
5. Prostacyclin naïve or patients pre-treated with SC or IV treprostinil prior to screening
6. A subject is eligible to participate in this study, as assessed by the investigator, if they are of:

   * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
   * Child-bearing potential - has a negative pregnancy test and is not lactating and, if sexually active, agrees to continue to use 2 reliable methods of contraception until study completion and for at least 30 days following the last dose of study drug. Examples of reliable birth control methods include true abstinence as a lifestyle choice (periodic sexual abstinence method is not acceptable); the use of oral contraceptives; a reliable barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices)

Exclusion Criteria:

1. Known intolerance to prostacyclin analogues
2. PH related to conditions other than specified above
3. Unrepaired congenital heart disease if surgery is planned within next 5 months
4. Subjects diagnosed with any lung disease
5. Acutely decompensated heart failure within previous 30 days from screening
6. Subjects who have had an atrial septostomy or potts shunt within the previous 6 months of screening
7. Any clinically significant laboratory abnormality that precludes initiation or continuation of treprostinil therapy
8. Moderate to severe hepatic dysfunction as defined by elevated liver function tests (aspartate aminotransferase or alanine aminotransferase) ≥3 times the upper limit of normal at Screening, or Child Pugh class B or C hepatic disease
9. Subjects who are pregnant or breastfeeding
10. Haematological abnormalities (e.g., severe anaemia, Hgb \<10 g/dL, leukopenia, White Blood Cells (WBC) \<2500/μL)
11. History of substance use disorder, unless a proof of abstinence ≥1 year is provided
12. Other concurrent severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
13. Participation in another clinical trial of an investigational drug or device (including with placebo) within 30 days or 5 half-lives prior to screening, which-ever is longer
14. Patients not able to handle pumps and infusion site if there is no parent, family member, guardian present in their household taking over pump handling or if they are not treated in hospital set-up

Where it's running

• Medizinische Universität Wien
  Vienna, State of Vienna, Austria Recruiting
• Necker-Enfants Malades Hospital, Paris
  Paris, Paris, France Recruiting
• Gottsegen National Cardiovascular Center
  Budapest, Budapest, Hungary Recruiting
• Pediatric Cardiac Center
  Bratislava, Slovakia Recruiting
• Ramón y Cajal University Hospital
  Madrid, Madrid, Spain Recruiting

Study contacts

• Study coordinator: Clinical Project Manager
• Email: trepaed@aop-health.com
• Phone: 4366488375206

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

• Once-daily treprostinil palmitil inhalation powder for PAH

  This study tests whether taking a daily inhaled treprostinil palmitil powder for 24 weeks improves exercise ability in adults with pulmonary arterial hypertension compared to a placebo.

  Recruiting at 39 sites Phase 3 Insmed Incorporated · Los Angeles, California and 38 other locations · NCT07481981

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.